Pathology
病理
基本信息
- 批准号:7141206
- 负责人:
- 金额:$ 9.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The Pathology Core is designed to provide the investigators of the Program Project with expert
pathologic evaluation of all soft tissue sarcomas (STS) that present to Memorial Sloan-Kettering Cancer
Center. The Core will provide a centralized, comprehensive facility for tissue-based research. The resource will
provide tissues and associated data in an equitable and ethical manner, provide professional expertise in
histo- and molecular pathology and assist and perform tissue-based experimentation. The human tissues
used for research studies are obtained under existing IRB-approved protocols. The specific aims are:
1. To provide consistent, expert pathologic characterization of all STS specimens resected at MSKCC,
including a description of gross appearance, histologic type, tumor grade, necrosis, and surgical margins.
2. To supervise the procurement of normal and neoplastic human tissue samples and maintain a bank of
frozen sarcoma tissue for special studies conducted under the different projects. This process ensures that
adequate amounts of correctly identified and processed tissue reach the appropriate laboratories.
3. To provide expert histologic review for individual projects, including tumor viability and assessment of
tumor response to various investigational agents used in different studies, either in post-treated surgical
specimens or xenografts. Histologic response assessment to various inhibitors will also be provided for the
preclinical in vivo mouse models, as well as histologic expertise for the murine knockout/transgenic models .
4. To assist in performing high-throughput tissue microarray (TMA) and interpreting immunohistochemical
(IHC) and in situ hybridization studies (ISH) for validation studies of various microarray projects. An ATA-27
Beecher Automated tissue arrayer will be used to construct TMAs of varying sarcoma types and
accompanying normal tissues. Quantitative image analysis of the IHC/ISH results will be performed using an
ACIS II (automated cellular imaging system) Chromavision slide scanner tissue arrayer. Assistance with the
development of the Clinical Tissue Microarray (ClinTMA) Database by the Bioinformatics Core will be
provided, and results will be entered into this database as continuous values.
These aims offer a substantial infrastructure to the STS Program Project and allows Core B to provide the
required services in a cost effective manner.
病理学核心旨在为计划项目的研究人员提供专家
所有出现纪念斯隆-凯特琳癌症的软组织肉瘤(STS)的病理学评价
中心核心将为基于组织的研究提供一个集中的综合设施。该资源将
以公平和道德的方式提供组织和相关数据,提供专业知识,
组织和分子病理学,并协助和执行组织为基础的实验。人类组织
用于研究的药物是根据现有IRB批准的方案获得的。具体目标是:
1.为提供在MSKCC切除的所有STS标本的一致、专业病理学表征,
包括大体外观、组织学类型、肿瘤分级、坏死和手术切缘的描述。
2.监督正常和肿瘤人体组织样本的采购,并维持一个
冷冻肉瘤组织,用于在不同项目下进行的特殊研究。该过程确保
足够量的正确识别和处理的组织到达适当的实验室。
3.为个别项目提供专家组织学审查,包括肿瘤活力和评估
肿瘤对不同研究中使用的各种研究药物的反应,无论是在治疗后的手术治疗中,
标本或异种移植物。还将提供对各种抑制剂的组织学反应评估,
临床前体内小鼠模型,以及鼠基因敲除/转基因模型的组织学专业知识。
4.协助进行高通量组织微阵列(TMA)和解释免疫组化
(IHC)以及原位杂交研究(ISH),用于各种微阵列项目的验证研究。ATA-27
比彻自动组织排列器将用于构建不同肉瘤类型的TMA,
伴随着正常组织。将使用免疫组织化学方法对IHC/ISH结果进行定量图像分析。
ACIS II(自动细胞成像系统)Chromavision载玻片扫描仪组织排列仪。帮扶与
由生物信息学核心开发的临床组织微阵列(ClinTMA)数据库将
提供,结果将作为连续值输入该数据库。
这些目标为STS计划项目提供了实质性的基础设施,并允许核心B提供
以具有成本效益的方式提供所需服务。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CRISTINA R ANTONESCU其他文献
CRISTINA R ANTONESCU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CRISTINA R ANTONESCU', 18)}}的其他基金
Novel therapeutics development and mechanisms of therapeutic resistance in gastrointestinal stromal tumor (GIST)
胃肠道间质瘤(GIST)的新疗法开发和耐药机制
- 批准号:
10932621 - 财政年份:2023
- 资助金额:
$ 9.88万 - 项目类别:
Novel therapeutics development and mechanisms of therapeutic resistance in gastrointestinal stromal tumor (GIST)
胃肠道间质瘤(GIST)的新疗法开发和耐药机制
- 批准号:
10468962 - 财政年份:2018
- 资助金额:
$ 9.88万 - 项目类别:
Novel therapeutics development and mechanisms of therapeutic resistance in gastrointestinal stromal tumor (GIST)
胃肠道间质瘤(GIST)的新疗法开发和耐药机制
- 批准号:
10016095 - 财政年份:2018
- 资助金额:
$ 9.88万 - 项目类别:
Novel therapeutics development and mechanisms of therapeutic resistance in gastrointestinal stromal tumor (GIST)
胃肠道间质瘤(GIST)的新疗法开发和耐药机制
- 批准号:
10247696 - 财政年份:2018
- 资助金额:
$ 9.88万 - 项目类别:
P1 - Molecular Mechanisms of KIT Signaling and Imatinib Resistance in GIST
P1 - GIST 中 KIT 信号传导和伊马替尼耐药的分子机制
- 批准号:
7976097 - 财政年份:2010
- 资助金额:
$ 9.88万 - 项目类别:
相似海外基金
Project 1: KSHV reprograms replication and metabolic activities in hypoxia
项目 1:KSHV 在缺氧条件下重新编程复制和代谢活动
- 批准号:
10714173 - 财政年份:2023
- 资助金额:
$ 9.88万 - 项目类别:
Targeting proteoglycan-mediated signaling in Ewing sarcoma
尤文肉瘤中靶向蛋白多糖介导的信号传导
- 批准号:
10591979 - 财政年份:2023
- 资助金额:
$ 9.88万 - 项目类别:
Next generation T cell therapies for mutant KRAS solid tumors
针对突变 KRAS 实体瘤的下一代 T 细胞疗法
- 批准号:
10731929 - 财政年份:2023
- 资助金额:
$ 9.88万 - 项目类别:
T cell immunity in a rare juvenile form of motor neuron disease
一种罕见的青少年运动神经元疾病中的 T 细胞免疫
- 批准号:
10595316 - 财政年份:2023
- 资助金额:
$ 9.88万 - 项目类别:
Discovery and characterization of exceptionally specific surface oncoprotein LIPI in Ewing Sarcoma
尤文肉瘤中异常特异性表面癌蛋白 LIPI 的发现和表征
- 批准号:
10721942 - 财政年份:2023
- 资助金额:
$ 9.88万 - 项目类别:
Kaposi Sarcoma in the Era of ART in Africa Program (KEAAP)
非洲抗逆转录病毒治疗时代的卡波西肉瘤计划 (KEAAP)
- 批准号:
10598769 - 财政年份:2023
- 资助金额:
$ 9.88万 - 项目类别:














{{item.name}}会员




